On June 16, 2022, the FTC unanimously voted to issue an enforcement policy statement putting Pharmacy Benefit Managers (PBMs) on notice that the payment of rebates and fees by drug manufacturers to PBMs resulting in the exclusion of lower-cost drug alternatives offered by competitors from the PBM’s formularies may violate competition and consumer protection laws.